
MPR Weekly Dose Podcast: Episode 11
This week we talk about the recall of an anti-anxiety med; Possible withdrawal of Makena; New MS treatment approved; IUD approved for up to six years; and time of day when meds taken could affect CVD ...
1 Nov 20195min

MPR Weekly Dose Podcast Episode 10
This week we talk about the resurrection of Biogen's novel Alzheimer treatment; A "landmark" approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for...
24 Okt 20197min

MPR Weekly Dose Podcast Episode 9
This week we talk about new treatment approvals for acute migraine, dry eye disease and schizophrenia; a new indication for Xarelto; and the Centers for Disease Control and Prevention issue an interim...
17 Okt 20196min

MPR Weekly Dose Podcast Episode 8
This week we talk about the FDA highlighting THC in the recent spate of vaping-related illnesses; Descovy's expanded approval; A new cream for acne; A treatment for the rare condition possibly behind ...
11 Okt 20195min

MPR Weekly Dose Podcast: Episode 7
This week: New Invokana approval; More ranitidine recalls lead CVS to suspend all sales; FDA has identifies 11 serious cybersecurity vulnerabilities that could affect medical devices and hospital netw...
4 Okt 20198min

MPR Weekly Dose Podcast: Episode 6
This week: A new tablet treatment for type 2 diabetes; Pancreatitis treatment gains Orphan Drug status; New approval for smallpox, monkeypox; An investigational treatment for Guillain-Barré Syndrome; ...
26 Sep 20196min

MPR Weekly Dose Podcast: Episode 5
This week: FDA votes on possible peanut allergy treatment; New risks ID'd with some breast cancer drugs; a topical solution for common warts edges nearer; Nitrosamine impurity identified in acid suppr...
20 Sep 20196min

MPR Weekly Dose Podcast: Episode 3
This week: New adjunct treatment for Parkinson disease; Pain med associated with hypoglycemia; New approval for active ankylosing spondylitis; Fast track designation for possible kidney disease therap...
30 Aug 20196min






















